BioAge Labs, Inc. BIOA
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
In January 2025, we announced the nomination of our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BGE-102 has a distinct mechanism and binding site from other NLRP3 inhibitors in development with issued patents covering both composition of matter and claims for the unique binding site.
In December 2025, we announced that BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement and high brain penetration.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $9.0M | $0 | — | — |
| R&D | $74.0M | $59.0M | $33.9M | — |
| SG&A | $27.8M | $19.2M | $14.5M | — |
| Total operating expenses | $101.8M | $78.2M | $48.4M | — |
| Operating income | -$92.8M | -$78.2M | -$48.4M | — |
| Interest expense | $697.0K | $2.4M | $7.8M | — |
| Pre-tax income | -$80.6M | -$71.1M | -$63.9M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$80.6M | -$71.1M | -$63.9M | — |
| EPS, basic | -2.24 | -6.63 | -38.17 | — |
| EPS, diluted | -2.24 | -6.63 | -38.17 | — |
| Shares, diluted (wtd. avg.) | 35.9M | 10.7M | 1.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $188.9M | $354.3M | $21.6M | — |
| Short-term investments | $92.2M | $0 | — | — |
| Receivables | $769.0K | $0 | — | — |
| Total current assets | $286.8M | $357.1M | $25.3M | — |
| Property, plant and equipment | $963.0K | $591.0K | $323.0K | — |
| Total assets | $294.9M | $358.2M | $25.9M | — |
| Accounts payable | $2.7M | $2.0M | $1.9M | — |
| Short-term debt | $2.6M | $6.0M | $6.0M | — |
| Total current liabilities | $20.1M | $27.8M | $58.2M | — |
| Long-term debt | $0 | $2.5M | $8.2M | — |
| Total liabilities | $22.8M | $35.1M | $66.6M | — |
| Retained earnings | -$333.4M | -$252.8M | -$181.7M | — |
| Total equity | $272.1M | $323.1M | -$173.4M | -$112.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$81.6M | -$51.5M | -$37.4M | — |
| Depreciation and amortisation | $200.0K | $200.0K | $200.0K | — |
| Stock-based compensation | $11.7M | $7.0M | $3.0M | — |
| Capital expenditure | $719.0K | $366.0K | $166.0K | — |
| Investing cash flow | -$95.2M | -$366.0K | -$266.0K | — |
| Financing cash flow | $11.5M | $381.2M | $34.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-120873.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $0 | $9.0M |
| Gross profit | — | — | — | — |
| Net income | — | -$63.9M | -$71.1M | -$80.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |